Comparison of Pericapsular Nerve Group (PENG) Block With a Combined Femoral, Sciatic, Lateral Femoral Cutaneous Nerve Block for Postoperative Analgesia in Secondary Total Hip Arthroplasty; (REVPET)

Vaud University Hospital Center

Status: Not yet enrolling

Conditions: Hip Arthroplasty Replacement; Post Operative Analgesia; Post Operative Pain, Acute

Treatments: Drug: Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound; Drug: Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT07109388

2025-00488

Details and patient eligibility

About

The aim of this clinical trial is to compare the analgesic effect of a pericapsular nerve group (PENG) block with a combined femoral, sciatic, lateral femoral cutaneous nerve block for postoperative analgesia in patients scheduled for secondary total hip arthroplasty. The primary objective of this study is to compare postoperative pain management between the PENG block and the combined block (femoral, sciatic, lateral femoral cutaneous) by measuring postoperative morphine consumption in each of the two groups.

Participants will be randomized into two groups. Patients assigned to the PENG group will receive a PENG block with ropivacaine, followed by a sham (sciatic) block, and spinal anesthesia with isobaric bupivacaine. Patients assigned to the combined block group will receive femoral, sciatic, lateral femoral cutaneous nerve blocks with ropivacaine, followed by spinal anesthesia with isobaric bupivacaine.

Full description

This is a single-center, prospective, superiority, randomized, double-blind, parallel-group study.

Patients will be randomized into two groups of 25 patients each, for a total enrollment plan of 50 patients. After written informed consent, patients will be allocated to one of the two groups according to a computer-generated randomization list.

The nerve blocks will be performed using ultrasound guidance.

During the surgery, 0.15 mg/kg of dexamethasone IV, 1 g paracetamol IV, 30 mg ketorolac IV, and 40 mg/kg magnesium IV will be given for postoperative analgesia.

In the PACU, pain management will be provided as needed with 2 mg of IV morphine at ten-minute intervals for pain scores >4. Once spinal motor block has resolved, the patients will be transferred to the surgical ward with a morphine patient-controlled analgesia (PCA) pump. The pump parameters will allow 2 mg boluses of morphine with a 10-minute lockout and a maximum dose of 40 mg in 4 hours.

Basal analgesia will be provided with paracetamol (1 g/6 h) and ibuprofen (400 mg/8 h). Ondansetron (4 mg IV) will be administered in case of nausea or vomiting.

A research assistant will conduct postoperative visits at 2 hours, 1 day, and 2 days postoperatively to record research data. Functional testing will be done on days 1 and 2 by physiotherapy personnel.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients
• ASA (American Society of Anaesthesiologists) I-III
• 18 years of age or older
• Patients scheduled for elective secundary hip arthroplasty
• Able to give written conformed consent autonomously

Exclusion criteria

• Refusal or inability to give consent
• Allergy to any of: ropivacaine, paracetamol, ibuprofen, ketorolac, morphine, ondansetron or dexamethasone
• Bleeding diathesis
• Neurological deficit of the operative side
• Existing preoperative opioid use
• Renal insufficiency (GFR<30ml/min according to the Cockroft-Gault formula)
• Hepatic insufficiency
• Morbid Obésity III

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups

PENG group

Experimental group

Description:

Pericapsular nerve group block

Treatment:

Drug: Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound

Combined nerve block

Active Comparator group

Description:

Combined femoral, sciatic, lateral femoral cutaneous nerve block

Treatment:

Drug: Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine